{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:58:33Z","timestamp":1781614713091,"version":"3.54.5"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ixekizumab, an interleukin 17A inhibitor, has demonstrated efficacy in improving clinical and patient-reported outcomes in axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). However, objective data regarding its effects on peripheral inflammation in joints and entheses, inflammation of the posterolateral spinal segments, and structural progression in the spine are lacking. In this study, we aim to address the abovementioned gaps by conducting a longitudinal investigation of the effects of ixekizumab on peripheral and axial inflammation and structural damage in patients with axSpA and PsA. Through comprehensive assessment using advanced imaging techniques such as whole-body magnetic resonance (WB-MRI) and detailed MRI evaluation of the spine, including MRI-based synthetic computed tomography (synthetic CT), and low-dose CT, we seek to investigate the therapeutic effectiveness of ixekizumab across different disease domains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>DAPHNE (EU-CT 2024-510746-14\u201300) is a 2-year open-label investigator-initiated multi-center study conducted in Denmark. Sixty-five patients with axSpA and PsA (\u226525 with each diagnosis; \u226510 PsA patients with imaging-documented axial involvement), with a clinical indication for biological disease-modifying antirheumatic drug therapy, will be treated with ixekizumab, and followed by clinical, laboratory, WB-MRI, radiography, and low dose CT of sacroiliac joints (SIJs) and spine. MRI will include T1-weighted and short tau inversion recovery (STIR) sequences and a sequence allowing the generation of CT-like \u201csynthetic CT\u201d MR images. Images will be evaluated by readers blinded for diagnosis and clinical and other imaging findings. Furthermore, new lesion definitions and evaluation methods for synthetic CT and low-dose CT will be sought developed and explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Currently, there are no data on the objective assessment of enthesitis, inflammation of the posterolateral segments of the spine, or structural progression in the spine using modern imaging during ixekizumab treatment neither in PsA nor axSpA. Thus, a longitudinal study hereof - the DAPHNE study - is anticipated to significantly improve our understanding of the diverse disease manifestations in axSpA and PsA, and how they respond to ixekizumab treatment. Additionally, the study will provide valuable insights into new and improved imaging examination and evaluation methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>EU-CT 2024-510746-14-00.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41927-025-00560-5","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:46:17Z","timestamp":1760615177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Detailed assessment of axial and peripheral entheses and joints in axial spondyloarthritis and psoriatic arthritis patients treated with ixekizumab (DAPHNE): design of a 2-year phase IV trial applying whole-body MRI, MRI-based synthetic CT, and CT"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8500-4064","authenticated-orcid":false,"given":"Simone Tromborg","family":"Willesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-6494","authenticated-orcid":false,"given":"Jakob M\u00f8llenbach","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6500-9263","authenticated-orcid":false,"given":"Susanne Juhl","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3690-467X","authenticated-orcid":false,"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"issue":"9783","key":"560_CR1","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/s0140-6736(11)60071-8","volume":"377","author":"M Dougados","year":"2011","unstructured":"Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377(9783):2127\u201337. https:\/\/doi.org\/10.1016\/s0140-6736(11)60071-8.","journal-title":"Lancet"},{"key":"560_CR2","doi-asserted-by":"crossref","unstructured":"Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl, 2):ii14\u201317. https:\/\/doi.org\/64\/suppl_2\/ii14.","DOI":"10.1136\/ard.2004.032482"},{"issue":"10089","key":"560_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/s0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73\u201384. https:\/\/doi.org\/10.1016\/s0140-6736(16)31591-4. [published Online First:20170120.","journal-title":"Lancet"},{"key":"560_CR4","first-page":"4","volume":"78","author":"A Boonen","year":"2006","unstructured":"Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl. 2006;78:4\u201311.","journal-title":"J Rheumatol Suppl"},{"key":"560_CR5","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(97)12004-9","volume":"352","author":"D McGonagle","year":"1998","unstructured":"McGonagle D, Gibbon W, Emery P. Classification of inflammatory arthritis by enthesitis. Lancet. 1998;352:1137\u201340.","journal-title":"Lancet"},{"issue":"10217","key":"560_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): A randomised, placebo-controlled trial. Lancet. 2020;395(10217):53\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(19)32971-X. [published Online First:20191205.","journal-title":"Lancet"},{"issue":"10163","key":"560_CR7","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"van der Heijde D","year":"2018","unstructured":"van der Heijde D, cheng-Chung Wei J, dos M D, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(18)31946-9. [published Online First:20181022.","journal-title":"Lancet"},{"key":"560_CR8","doi-asserted-by":"publisher","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: Results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209709. [published Online First:20160823.","DOI":"10.1136\/annrheumdis-2016-209709"},{"issue":"10086","key":"560_CR9","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: Results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(17)31429-0. [published Online First:20170524.","journal-title":"Lancet"},{"key":"560_CR10","unstructured":"Felbo SK, Terslev L, \u00d8stergaard M. Imaging in peripheral and axial psoriatic arthritis: Contributions to diagnosis, follow-up, prognosis and knowledge of pathogenesis. Clin Exp Rheumatol. 2018, 36 Suppl 114(5):24\u201334. 13349 [pii]."},{"key":"560_CR11","doi-asserted-by":"publisher","unstructured":"Poggenborg RP, Pedersen SJ, Eshed I, et al. Head-to-toe whole-body MRI in psoriatic arthritis, axial spondyloarthritis and healthy subjects: First steps towards global inflammation and damage scores of peripheral and axial joints. Rheumatol (oxford). 2015;54(6):1039\u201349. https:\/\/doi.org\/10.1093\/rheumatology\/keu439.","DOI":"10.1093\/rheumatology\/keu439"},{"key":"560_CR12","doi-asserted-by":"publisher","unstructured":"Krabbe S, \u00d8stergaard M, Eshed I, et al. Whole-body magnetic resonance imaging in axial spondyloarthritis: Reduction of sacroiliac, spinal, and Entheseal inflammation in a placebo-controlled trial of Adalimumab. J Rheumatol. 2018. https:\/\/doi.org\/10.3899\/jrheum.170408.","DOI":"10.3899\/jrheum.170408"},{"key":"560_CR13","doi-asserted-by":"publisher","unstructured":"\u00d8stergaard M, Eshed I, Althoff CE, et al. Whole-body magnetic resonance imaging in inflammatory arthritis: Systematic literature review and first steps toward standardization and an OMERACT scoring system. J Rheumatol. 2017;44(11):1699\u2013705. https:\/\/doi.org\/10.3899\/jrheum.161114.","DOI":"10.3899\/jrheum.161114"},{"key":"560_CR14","doi-asserted-by":"publisher","unstructured":"Krabbe S, Eshed I, Gandjbakhch F, et al. Development and validation of an OMERACT MRI whole-body score for inflammation in peripheral joints and entheses in inflammatory arthritis (MRI-WIPE). J Rheumatol. 2019;46(9):1215\u201321. https:\/\/doi.org\/10.3899\/jrheum.181084.","DOI":"10.3899\/jrheum.181084"},{"issue":"9","key":"560_CR15","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/art.24561","volume":"61","author":"WJ Rennie","year":"2009","unstructured":"Rennie WJ, Dhillon SS, Conner-Spady B, et al. Magnetic resonance imaging assessment of spinal inflammation in ankylosing spondylitis: Standard clinical protocols may omit inflammatory lesions in thoracic vertebrae. Arthritis Rheum. 2009;61(9):1187\u201393.","journal-title":"Arthritis Rheum"},{"key":"560_CR16","doi-asserted-by":"publisher","unstructured":"Krabbe S, Sorensen IJ, Jensen B, et al. Inflammatory and structural changes in vertebral bodies and posterior elements of the spine in axial spondyloarthritis: Construct validity, responsiveness and discriminatory ability of the anatomy-based CANDEN scoring system in a randomised placebo-controlled trial. RMD Open. 2018;4(1):e000624. https:\/\/doi.org\/10.1136\/rmdopen-2017-000624.","DOI":"10.1136\/rmdopen-2017-000624"},{"issue":"4","key":"560_CR17","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/art.21337","volume":"53","author":"WP Maksymowych","year":"2005","unstructured":"Maksymowych WP, Inman RD, Salonen D, et al. Spondyloarthritis research consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis Rheum. 2005;53(4):502\u201309.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"560_CR18","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/art.21563","volume":"54","author":"H Haibel","year":"2006","unstructured":"Haibel H, Rudwaleit M, Brandt HC, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum. 2006;54(2):678\u201381.","journal-title":"Arthritis Rheum"},{"issue":"84","key":"560_CR19","first-page":"3","volume":"36","author":"RGW Lambert","year":"2009","unstructured":"Lambert RGW, Pedersen SJ, Maksymowych WP, et al. Active inflammatory lesions detected by magnetic resonance imaging in the spine of patients with spondyloarthritis - definitions, assessment system and reference image set. J Rheumatol. 2009;36 (Suppl, 84):3\u201317.","journal-title":"J Rheumatol"},{"issue":"84","key":"560_CR20","first-page":"18","volume":"36","author":"M \u00d8stergaard","year":"2009","unstructured":"\u00d8stergaard M, Maksymowych WP, Pedersen SJ, et al. Structural lesions detected by magnetic resonance imaging in the spine of patients with spondyloarthritis - definitions, assessment system and reference image set. J Rheumatol. 2009;36(Suppl, 84):18\u201334.","journal-title":"J Rheumatol"},{"issue":"10","key":"560_CR21","first-page":"2048","volume":"32","author":"van der Heijde D","year":"2005","unstructured":"van der Heijde D, R L. Selection of a method for scoring radiographs for ankylosing spondylitis clinical trials, by the assessment in ankylosing spondylitis working group and OMERACT. J Rheumatol. 2005;32(10):2048\u201349.","journal-title":"J Rheumatol"},{"issue":"8","key":"560_CR22","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1002\/art.20446","volume":"50","author":"AJ Wanders","year":"2004","unstructured":"Wanders AJ, Landewe RB, Spoorenberg A, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the outcome measures in rheumatology clinical trials filter. Arthritis Rheum. 2004;50(8):2622\u201332. https:\/\/doi.org\/10.1002\/art.20446","journal-title":"Arthritis Rheum"},{"issue":"10","key":"560_CR23","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1002\/art.23901","volume":"58","author":"van der Heijde D","year":"2008","unstructured":"van der Heijde D, R L, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58(10):3063\u201370. https:\/\/doi.org\/10.1002\/art.23901.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"560_CR24","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1186\/ar2794","volume":"11","author":"van der Heijde D","year":"2009","unstructured":"van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009;11(4):R127. https:\/\/doi.org\/10.1186\/ar2794. [published Online First:20090824.","journal-title":"Arthritis Res Ther"},{"key":"560_CR25","doi-asserted-by":"publisher","unstructured":"Diekhoff T, Hermann KG, Greese J, et al. Comparison of MRI with radiography for detecting structural lesions of the sacroiliac joint using CT as standard of reference: Results from the SIMACT study. Ann Rheum Dis. 2017;76(9):1502\u201308. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210640.","DOI":"10.1136\/annrheumdis-2016-210640"},{"issue":"6","key":"560_CR26","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1136\/ard-2023-225444","volume":"83","author":"ST Willesen","year":"2024","unstructured":"Willesen ST, Hadsbjerg AE, M\u00f8ller JM, et al. MRI-based synthetic CT: A new method for structural damage assessment in the spine in patients with axial spondyloarthritis - a comparison with low-dose CT and radiography. Ann Rheum Dis. 2024;83(6):807\u201315. https:\/\/doi.org\/10.1136\/ard-2023-225444. [published Online First:20240515.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"560_CR27","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1136\/ard.2009.108217","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Landewe R, van der Heijde D, et al. The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part I): Classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009;68(6):770\u201376.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"560_CR28","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, et al. The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): Validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383. https:\/\/doi.org\/10.1136\/ard.2009.108233. [published Online First:20090317.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"560_CR29","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1136\/annrheumdis-2015-208642","volume":"75","author":"RG Lambert","year":"2016","unstructured":"Lambert RG, Bakker PA, van der Heijde D, et al. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: Update by the ASAS MRI working group. Ann Rheumatic Dis. 2016;75(11):1958\u201363. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208642. [published Online First:2016\/01\/16.","journal-title":"Ann Rheumatic Dis"},{"issue":"4","key":"560_CR30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"van der Linden S","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361\u201368. https:\/\/doi.org\/10.1002\/art.1780270401.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"560_CR31","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373. https:\/\/doi.org\/10.1002\/art.21972.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"560_CR32","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/mrm.28008","volume":"83","author":"MC Florkow","year":"2020","unstructured":"Florkow MC, Zijlstra F, Willemsen K, et al. Deep learning-based MR-to-CT synthesis: The influence of varying gradient echo-based MR images as input channels. Magn Reson Med. 2020;83(4):1429\u201341. https:\/\/doi.org\/10.1002\/mrm.28008. [published Online First:20191008.","journal-title":"Magn Reson Med"},{"issue":"1","key":"560_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/ard.2004.020503","volume":"64","author":"MC Creemers","year":"2005","unstructured":"Creemers MC, Franssen MJ, van\u2019t Hof MA, et al. Assessment of outcome in ankylosing spondylitis: An extended radiographic scoring system. Ann Rheum Dis. 2005;64(1):127\u201329. https:\/\/doi.org\/10.1136\/ard.2004.020503. [published Online First:20040329.","journal-title":"Ann Rheum Dis"},{"key":"560_CR34","doi-asserted-by":"publisher","unstructured":"Maksymowych WP, Wichuk S, Chiowchanwisawakit P, et al. Development and preliminary validation of the spondyloarthritis research consortium of Canada magnetic resonance imaging sacroiliac joint structural score. J Rheumatol. 2015;42(1):79\u201386. https:\/\/doi.org\/10.3899\/jrheum.140519.","DOI":"10.3899\/jrheum.140519"},{"issue":"6","key":"560_CR35","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/ard.2008.101501","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper J, van der Heijde D, Landew\u00e9 R, et al. New criteria for inflammatory back pain in patients with chronic back pain: A real patient exercise by experts from the assessment of SpondyloArthritis international society (ASAS). Ann Rheum Dis. 2009;68(6):784\u201388. https:\/\/doi.org\/10.1136\/ard.2008.101501. [published Online First:2009\/01\/17.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"560_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P Machado","year":"2011","unstructured":"Machado P, Landew\u00e9 R, Lie E, et al. Ankylosing spondylitis disease activity score (ASDAS): Defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70(1):47\u201353. https:\/\/doi.org\/10.1136\/ard.2010.138594. [published Online First:2010\/11\/12.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"560_CR37","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1136\/ard.2007.074724","volume":"67","author":"van der Heijde D","year":"2008","unstructured":"van der Heijde D, R L, Feldtkeller E. Proposal of a linear definition of the bath ankylosing spondylitis metrology index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis. 2008;67(4):489\u201393. https:\/\/doi.org\/10.1136\/ard.2007.074724. [published Online First:2007\/08\/31.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"560_CR38","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"G Wells","year":"2009","unstructured":"Wells G, Becker JC, Teng J, et al. Validation of the 28-joint disease activity score (DAS28) and European league against rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68(6):954\u201360. https:\/\/doi.org\/10.1136\/ard.2007.084459. [published Online First:2008\/05\/21.","journal-title":"Ann Rheum Dis"},{"issue":"5 Suppl 39","key":"560_CR39","first-page":"S100","volume":"23","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Smolen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S100\u20138. [published Online First: 2005\/11\/09.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"560_CR40","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1136\/ard.2007.084244","volume":"68","author":"WP Maksymowych","year":"2009","unstructured":"Maksymowych WP, Mallon C, Morrow S, et al. Development and validation of the Spondyloarthritis research consortium of Canada (SPARCC) Enthesitis index. Ann Rheum Dis. 2009;68(6):948\u201353. https:\/\/doi.org\/10.1136\/ard.2007.084244. [published Online First:2008\/06\/06.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"560_CR41","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59(5):686\u201391. https:\/\/doi.org\/10.1002\/art.23568. [published Online First:2008\/04\/29.","journal-title":"Arthritis Rheum"},{"key":"560_CR42","doi-asserted-by":"publisher","unstructured":"Mease PJ. Measures of psoriatic arthritis: Tender and swollen joint assessment, psoriasis area and severity index (PASI), nail psoriasis severity index (NAPSI), modified nail psoriasis severity index (mNAPSI), Mander\/Newcastle Enthesitis index (MEI), Leeds Enthesitis index (LEI), Spondyloarthritis research consortium of Canada (SPARCC), Maastricht ankylosing spondylitis Enthesis, score (MASES), Leeds dactylitis index (LDI), patient global for psoriatic arthritis, dermatology life quality index (DLQI), psoriatic arthritis quality of life (PsAQOL), functional assessment of chronic illness therapy-fatigue (FACIT-F), psoriatic arthritis response criteria (PsARC), psoriatic arthritis joint activity index (PsAJAI), disease activity in psoriatic arthritis (DAPSA), and composite psoriatic disease activity index (CPDAI). Arthritis Care Res (hoboken). 2011;63Suppl, 11):S64\u201385. https:\/\/doi.org\/10.1002\/acr.20577. [published Online First:2012\/05\/25.","DOI":"10.1002\/acr.20577"},{"issue":"2","key":"560_CR43","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/art.1780330203","volume":"33","author":"F Wolfe","year":"1990","unstructured":"Wolfe F, Smythe HA, Yunus MB, et al. The American college of rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum. 1990;33(2):160\u201372. https:\/\/doi.org\/10.1002\/art.1780330203.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"560_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjd.12290","volume":"169","author":"J Rhodes","year":"2013","unstructured":"Rhodes J, Clay C, Phillips M. The surface area of the hand and the palm for estimating percentage of total body surface area: Results of a meta-analysis. Br J Dermatol. 2013;169(1):76\u201384. https:\/\/doi.org\/10.1111\/bjd.12290. [published Online First:2013\/03\/02.","journal-title":"Br J Dermatol"},{"issue":"1","key":"560_CR45","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/rheumatology\/35.1.66","volume":"35","author":"SD Jones","year":"1996","unstructured":"Jones SD, Steiner A, Garrett SL, et al. The bath ankylosing spondylitis patient global score (BAS-G). Br J Rheumatol. 1996;35(1):66\u201371. https:\/\/doi.org\/10.1093\/rheumatology\/35.1.66. [published Online First:1996\/01\/01.","journal-title":"Br J Rheumatol"},{"key":"560_CR46","doi-asserted-by":"publisher","unstructured":"Zochling J. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing spondylitis disease activity score (ASDAS), ankylosing spondylitis quality of life scale (ASQoL), Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI). Bath Ankyl Spondylitis Global Score (bas-G), Bath Ankyl Spondylitis Metrol Index (BASMI), Dougados Funct Index (DFI), And Health Assess Questionnaire For The Spondylarthropathies (haq-S). Arthritis Care Res (hoboken). 2011;63Suppl, 11):S47\u201358. https:\/\/doi.org\/10.1002\/acr.20575. [published Online First:2012\/05\/25.","DOI":"10.1002\/acr.20575"},{"issue":"12","key":"560_CR47","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: The Bath ankylosing spondylitis disease activity index. J Rheumatol. 1994;21(12):2286\u201391. [published Online First: 1994\/12\/01.","journal-title":"J Rheumatol"},{"issue":"12","key":"560_CR48","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: The development of the bath ankylosing spondylitis functional index. J Rheumatol. 1994;21(12):2281\u201385. [published Online First: 1994\/12\/01.","journal-title":"J Rheumatol"},{"issue":"7","key":"560_CR49","first-page":"946","volume":"17","author":"LH Daltroy","year":"1990","unstructured":"Daltroy LH, Larson MG, Roberts NW, et al. A modification of the health assessment questionnaire for the spondyloarthropathies. J Rheumatol. 1990;17(7):946\u201350. [published Online First: 1990\/07\/01.","journal-title":"J Rheumatol"},{"issue":"5","key":"560_CR50","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: A measure of health status from the EuroQol group. Ann Med. 2001;33(5):337\u201343. https:\/\/doi.org\/10.3109\/07853890109002087. [published Online First:2001\/08\/09.","journal-title":"Ann Med"},{"issue":"2","key":"560_CR51","doi-asserted-by":"publisher","first-page":"e000311","DOI":"10.1136\/rmdopen-2016-000311","volume":"2","author":"U Kiltz","year":"2016","unstructured":"Kiltz U, van der Heijde D, Boonen A, et al. Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS health index and the environmental item set: Translation and cross-cultural adaptation into 15 languages. RMD Open. 2016;2(2):e000311. https:\/\/doi.org\/10.1136\/rmdopen-2016-000311.","journal-title":"RMD Open"},{"issue":"1","key":"560_CR52","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/art.22469","volume":"57","author":"WP Maksymowych","year":"2007","unstructured":"Maksymowych WP, Richardson R, Mallon C, et al. Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis. Arthritis Rheum. 2007;57(1):133\u201339. https:\/\/doi.org\/10.1002\/art.22469. [published Online First:2007\/02\/03.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"560_CR53","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","volume":"73","author":"L Gossec","year":"2014","unstructured":"Gossec L, de Wit M, Kiltz U, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: Elaboration and preliminary validation of the psoriatic arthritis impact of disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73(6):1012\u201319. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205207.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"560_CR54","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/acr.20140","volume":"62","author":"F Wolfe","year":"2010","unstructured":"Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American college of rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (hoboken). 2010;62(5):600\u201310. https:\/\/doi.org\/10.1002\/acr.20140.","journal-title":"Arthritis Care Res (hoboken)"},{"issue":"11","key":"560_CR55","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1093\/rheumatology\/keaa153","volume":"59","author":"S Krabbe","year":"2020","unstructured":"Krabbe S, Eshed I, S\u00f8rensen IJ, et al. Novel whole-body magnetic resonance imaging response and remission criteria document diminished inflammation during golimumab treatment in axial spondyloarthritis. Rheumatol (oxford). 2020;59(11):3358\u201368. https:\/\/doi.org\/10.1093\/rheumatology\/keaa153.","journal-title":"Rheumatol (oxford)"},{"issue":"9","key":"560_CR56","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/acr.25358","volume":"76","author":"P Mease","year":"2024","unstructured":"Mease P, Reed G, Ogdie A, et al. Prevalence of fibromyalgia and widespread pain in psoriatic arthritis: Association with disease severity assessment in a large US registry. Arthritis Care Res (hoboken). 2024;76(9):1313\u201321. https:\/\/doi.org\/10.1002\/acr.25358. [published Online First:20240717.","journal-title":"Arthritis Care Res (hoboken)"},{"key":"560_CR57","doi-asserted-by":"publisher","unstructured":"Mease PJ. Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment. Curr Opin Rheumatol. 2017;29(4):304\u201310. https:\/\/doi.org\/10.1097\/bor.0000000000000388.","DOI":"10.1097\/bor.0000000000000388"},{"key":"560_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-222081","author":"X Baraliakos","year":"2022","unstructured":"Baraliakos X, Ostergaard M, Lambert RG, et al. MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group. Ann Rheum Dis. 2022. https:\/\/doi.org\/10.1136\/annrheumdis-2021-222081. [published Online First:20220524.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"560_CR59","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1136\/annrheumdis-2022-222747","volume":"82","author":"V Navarro-Comp\u00e1n","year":"2023","unstructured":"Navarro-Comp\u00e1n V, Boel A, Boonen A, et al. Instrument selection for the ASAS core outcome set for axial spondyloarthritis. Ann Rheum Dis. 2023;82(6):763\u201372. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222747.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"560_CR60","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/bor.0000000000000803","volume":"33","author":"RGW Lambert","year":"2021","unstructured":"Lambert RGW, Hermann KGA, Diekhoff T. Low-dose computed tomography for axial spondyloarthritis: Update on use and limitations. Curr Opin Rheumatol. 2021;33(4):326\u201332. https:\/\/doi.org\/10.1097\/bor.0000000000000803.","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"560_CR61","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s11926-022-01075-5","volume":"24","author":"T Diekhoff","year":"2022","unstructured":"Diekhoff T, Hermann KGA, Lambert RG. Future of low-dose computed tomography and dual-energy computed tomography in axial Spondyloarthritis. Curr Rheumatol Rep. 2022;24(6):198\u2013205. https:\/\/doi.org\/10.1007\/s11926-022-01075-5. [published Online First:20220409.","journal-title":"Curr Rheumatol Rep"},{"key":"560_CR62","doi-asserted-by":"publisher","unstructured":"Stal R, Ramiro S, Baraliakos X, et al. Good construct validity of the CT syndesmophyte score (CTSS) in patients with radiographic axial spondyloarthritis. RMD Open. 2023;9(1). https:\/\/doi.org\/10.1136\/rmdopen-2022-002959.","DOI":"10.1136\/rmdopen-2022-002959"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00560-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00560-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00560-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:32:19Z","timestamp":1781613139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41927-025-00560-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["560"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00560-5","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is approved by the Danish Ethics Committee through the Clinical Trials Information System (CTIS), EU-CT 2024 -510746-14\u201300. Signed informed consent to participate in the study is obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"STW none. JMM none. SJP has received grants and contracts from Innovation Fund Denmark and Nordic Bioscience A\/S, consulting fees, speaking fees, and\/or research support from AbbVie, Novartis, MSD, Pfizer, and UCB. M\u00d8 has received research grants from Abbvie, BMS, Merck, Novartis and UCB, and speaker and\/or consultancy fees from Abbvie, BMS, Celgene, Eli - Lilly, Galapagos, Gilead, Janssen, MEDAC, Merck, Novartis, Pfizer, Sandoz, and UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}